Evolocumab intensive lipid-lowering therapy on prognosis of post-cerebral infarction depression

Table 5 Cognitive function and functional outcomes at 24 weeks, n (%)/mean ± SD

Outcome measure	Intensive group (n = 72)	Standard group (n = 72)	P value
Global cognitive function
MoCA total score	26.2 ± 1.9	23.8 ± 2.5	< 0.001
Change from baseline	+4.4 ± 2.1	+2.3 ± 1.8	< 0.001
MoCA ≥ 26 (normal cognition)	48 (66.7)	28 (38.9)	< 0.001
Functional independence
Barthel Index	86.5 ± 12.3	76.8 ± 15.7	< 0.001
Change from baseline	+23.7 ± 8.9	+13.4 ± 7.2	< 0.001
mRS 0-2 (good outcome)	52 (72.2)	37 (51.4)	0.009
Mean mRS score	1.8 ± 0.9	2.4 ± 1.1	0.001
Quality of life (SF-36)
Physical component score	45.8 ± 8.2	39.2 ± 9.1	< 0.001
Mental component score	48.5 ± 7.6	38.7 ± 8.9	< 0.001

A positive change indicates improvement. MoCA: Montreal Cognitive Assessment; mRS: Modified Rankin Scale; SF-36: 36-Item Short Form Health Survey.